Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07355335 · ClinicalTrials.gov registry record · Phase 1
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07355335: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07355335 is a Phase 1 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07355335, a Phase 1 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Interventions
- DRUG Ziftomenib
- DRUG Mezigdomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-07-09 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07355335
The ClinicalTrials.gov registry entry for NCT07355335 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ziftomenib is the first listed.
NCT07355335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07355335 about?
NCT07355335 is a clinical study titled "Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML". The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
What is the current status of trial NCT07355335?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-07-09. Estimated completion is 2028-01-01.
What interventions are being tested in trial NCT07355335?
The interventions under investigation include: Ziftomenib (DRUG), Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT07355335?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.